NEW YORK ( TheStreet) -- Simcere Pharmaceutical Group Shs Sponsored (NYSE: SCR) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Highlights from the ratings report include:
  • Compared to where it was a year ago today, the stock is now trading at a higher level, reflecting both the market's overall trend during that period and the fact that the company's earnings growth has been robust. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
  • SIMCERE PHARMACTCL GRP -ADR reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. We feel that this trend should continue. During the past fiscal year, SIMCERE PHARMACTCL GRP -ADR increased its bottom line by earning $0.46 versus $0.05 in the prior year. This year, the market expects an improvement in earnings ($0.53 versus $0.46).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 100.8% when compared to the same quarter one year prior, rising from $5.71 million to $11.46 million.
  • Despite its growing revenue, the company underperformed as compared with the industry average of 10.8%. Since the same quarter one year prior, revenues slightly increased by 5.9%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • SCR's debt-to-equity ratio is very low at 0.26 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.13, which illustrates the ability to avoid short-term cash problems.

Simcere Pharmaceutical Group develops, manufactures, and markets branded generic and proprietary pharmaceuticals in China. The company has a P/E ratio of 19.8, above the average drugs industry P/E ratio of 19.3 and above the S&P 500 P/E ratio of 17.7. Simcere Pharmaceutical Group Shs Sponsored has a market cap of $507.3 million and is part of the health care sector and drugs industry. Shares are down 14.5% year to date as of the close of trading on Wednesday.

You can view the full Simcere Pharmaceutical Group Shs Sponsored Ratings Report or get investment ideas from our investment research center.
null

If you liked this article you might like

Simcere Pharmaceutical Group Stock Downgraded (SCR)

Simcere Pharmaceutical Group Stock Downgraded (SCR)

Simcere Pharmaceutical Group Stock Downgraded (SCR)

Simcere Pharmaceutical Group Stock Upgraded (SCR)

Dow Sets Another Record as Stocks Rise